ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above Fifty Day Moving Average of $57.71

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $57.71 and traded as high as $62.33. ProShares Ultra Nasdaq Biotechnology shares last traded at $62.29, with a volume of 10,764 shares changing hands.

ProShares Ultra Nasdaq Biotechnology Trading Up 2.4 %

The business has a 50-day simple moving average of $57.71 and a 200 day simple moving average of $56.82.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 3rd. Investors of record on Wednesday, June 26th were issued a dividend of $0.2648 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.70%. The ex-dividend date was Wednesday, June 26th. This is an increase from ProShares Ultra Nasdaq Biotechnology’s previous quarterly dividend of $0.04.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

Several large investors have recently added to or reduced their stakes in the stock. Simplex Trading LLC raised its holdings in ProShares Ultra Nasdaq Biotechnology by 5,408.9% in the 4th quarter. Simplex Trading LLC now owns 2,479 shares of the exchange traded fund’s stock worth $141,000 after purchasing an additional 2,434 shares in the last quarter. Clarity Capital Partners LLC bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 4th quarter valued at about $201,000. Palumbo Wealth Management LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the fourth quarter valued at about $228,000. Texas Capital Bank Wealth Management Services Inc bought a new position in ProShares Ultra Nasdaq Biotechnology in the first quarter worth about $288,000. Finally, Westwood Wealth Management purchased a new stake in ProShares Ultra Nasdaq Biotechnology in the first quarter worth about $575,000.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.